Alnylam’s slump deepens; Q2 earnings roundup; and morenews2026-08-01T10:00:38+00:00August 1st, 2026|Endpoints News|
AbbVie touts strong momentum for Skyrizi despite rising competitionnews2026-07-31T18:22:56+00:00July 31st, 2026|Endpoints News|
Pharma groups back changes to 340B rebate pilotnews2026-07-31T17:22:21+00:00July 31st, 2026|Endpoints News|
Moderna’s norovirus vaccine readout is delayed because of too few infectionsnews2026-07-31T16:36:25+00:00July 31st, 2026|Endpoints News|
Novo Nordisk rocked by late-stage cardiovascular drug failurenews2026-07-31T15:35:15+00:00July 31st, 2026|Endpoints News|
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPOnews2026-07-31T14:59:38+00:00July 31st, 2026|Endpoints News|
Ionis’ top scientist Frank Bennett to retire; Recursion selects its first AI chiefnews2026-07-31T11:00:06+00:00July 31st, 2026|Endpoints News|
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancernews2026-07-31T10:42:02+00:00July 31st, 2026|Endpoints News|
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trialnews2026-07-31T07:24:14+00:00July 31st, 2026|Endpoints News|
Apnimed raises $192M IPO for potential 2027 sleep apnea drug launchnews2026-07-31T07:18:16+00:00July 31st, 2026|Endpoints News|